Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 06 Aug 2024
Reviewer's report:
The study is well-reported for the South Korean experience.  The only suggestion I have is to
provide data on dose-escalation and outcomes for dose-escalation.
I have no other major concerns or critiques.
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 06 Aug 2024
Reviewer's report:
The study is well-reported for the South Korean experience.  The only suggestion I have is to
provide data on dose-escalation and outcomes for dose-escalation.
I have no other major concerns or critiques.
Please review this paper.
user
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 4 Date: 06 Aug 2024
Reviewer's report:
The study is well-reported for the South Korean experience.  The only suggestion I have is to
provide data on dose-escalation and outcomes for dose-escalation.
I have no other major concerns or critiques.
assistant